BackgroundHeart failure (HF) is a syndrome that leads to poor outcome in advanced forms. The
neurohormonal blockade modifies this natural history; however, it is often
suboptimal. ObjectiveThe aim of this study is to assess at what percentage cardiologists used to
treating HF can prescribe target doses of drugs of proven efficacy. MethodsA total of 104 outpatients with systolic dysfunction were consecutively enrolled,
all under stabilized treatment. Demographic and treatment data were evaluated and
the doses achieved were verified. The findings are shown as percentages and
correlations are made between different variables. ResultsThe mean age of patients was 64.1 ± 14.2 years, with SBP =115.4 ± 15.3, HR = 67.8
± 9.4 bpm, weight = 76.0 ± 17.0 kg and sinus rhythm (90.4%). As for treatment,
93.3% received a RAS blocker (ACEI 52.9%), all received beta-blockers (BB), the
most often prescribed being carvedilol (92.3%). As for the doses: 97.1% of those
receiving an ARB were below the optimal dose and of those who received ACEI, 52.7%
received an optimized dose. As for the BB, target doses were prescribed to 76.0%
of them. In this group of patients, most with BB target dose, it can be seen that
36.5% had HR ≥ 70 bpm in sinus rhythm. ConclusionCardiologists used to treating HF can prescribe target doses of ACEI and BB to
most patients. Even though they receive the recommended doses, about one third of
patients persists with HR > 70 bpm and should have their treatment
optimized.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.